nach oben

Erschienen in:

31.08.2023 | Original Communication

Volumetric changes and clinical trajectories in Parkinson’s disease: a prospective multicentric study

verfasst von: Ana Marques, Elise Macias, Bruno Pereira, Elodie Durand, Carine Chassain, Tiphaine Vidal, Luc Defebvre, Nicolas Carriere, Valerie Fraix, Elena Moro, Stéphane Thobois, Elise Metereau, Graziella Mangone, Marie Vidailhet, Jean-Christophe Corvol, Stéphane Lehéricy, Nicolas Menjot de Champfleur, Christian Geny, Umberto Spampinato, Wassilios G. Meissner, Solène Frismand, Emmanuelle Schmitt, Anne Doé de Maindreville, Christophe Portefaix, Philippe Remy, Gilles Fénelon, Jean Luc Houeto, Olivier Colin, Olivier Rascol, Patrice Peran, Jean-Marie Bonny, Maria Livia Fantini, Franck Durif, The R2* Study Group

Erschienen in: Journal of Neurology | Ausgabe 12/2023

Einloggen, um Zugang zu erhalten

Abstract

Background

Longitudinal measures of structural brain changes using MRI in relation to clinical features and progression patterns in PD have been assessed in previous studies, but few were conducted in well-defined and large cohorts, including prospective clinical assessments of both motor and non-motor symptoms.

Objective

We aimed to identify brain volumetric changes characterizing PD patients, and determine whether regional brain volumetric characteristics at baseline can predict motor, psycho-behavioral and cognitive evolution at one year in a prospective cohort of PD patients.

Methods

In this multicentric 1 year longitudinal study, PD patients and healthy controls from the MPI-R2* cohort were assessed for demographical, clinical and brain volumetric characteristics. Distinct subgroups of PD patients according to motor, cognitive and psycho-behavioral evolution were identified at the end of follow-up.

Results

One hundred and fifty PD patients and 73 control subjects were included in our analysis. Over one year, there was no significant difference in volume variations between PD and control subjects, regardless of the brain region considered. However, we observed a reduction in posterior cingulate cortex volume at baseline in PD patients with motor deterioration at one year (p = 0.017). We also observed a bilateral reduction of the volume of the amygdala (p = 0.015 and p = 0.041) and hippocampus (p = 0.015 and p = 0.053) at baseline in patients with psycho-behavioral deterioration, regardless of age, dopaminergic treatment and center.

Conclusion

Brain volumetric characteristics at baseline may predict clinical trajectories at 1 year in PD as posterior cingulate cortex atrophy was associated with motor decline, while amygdala and hippocampus atrophy were associated with psycho-behavioral decline.

Nur mit Berechtigung zugänglich

Greenland JC, Williams-Gray CH, Barker RA (2019) The clinical heterogeneity of Parkinson’s disease and its therapeutic implications. Eur J Neurosci 49:328–338. https://doi.org/10.1111/ejn.14094CrossRefPubMed

Schrag A, Schott JM (2006) Epidemiological, clinical, and genetic characteristics of early-onset parkinsonism. Lancet Neurol 5:355–363. https://doi.org/10.1016/S1474-4422(06)70411-2CrossRefPubMed

Yang J, Burciu RG, Vaillancourt DE (2018) Longitudinal Progression Markers of Parkinson’s Disease: Current View on Structural Imaging. Curr Neurol Neurosci Rep 18:83. https://doi.org/10.1007/s11910-018-0894-7CrossRefPubMedPubMedCentral

McGhee DJ, Royle PL, Thompson PA, Wright DE, Zajicek JP, Counsell CE (2013) A systematic review of biomarkers for disease progression in Parkinson’s disease. BMC Neurol 13:35. https://doi.org/10.1186/1471-2377-13-35CrossRefPubMedPubMedCentral

Sarasso E, Agosta F, Piramide N, Filippi M (2021) Progression of grey and white matter brain damage in Parkinson’s disease: a critical review of structural MRI literature. J Neurol 268:3144–3179. https://doi.org/10.1007/s00415-020-09863-8CrossRefPubMed

Filippi M, Sarasso E, Piramide N, Stojkovic T, Stankovic I, Basaia S, Fontana A, Tomic A, Markovic V, Stefanova E, Kostic VS, Agosta F (2020) Progressive brain atrophy and clinical evolution in Parkinson’s disease. Neuroimage Clin 28:102374. https://doi.org/10.1016/j.nicl.2020.102374CrossRefPubMedPubMedCentral

Mak E, Su L, Williams GB, Firbank MJ, Lawson RA, Yarnall AJ, Duncan GW, Owen AM, Khoo TK, Brooks DJ, Rowe JB, Barker RA, Burn DJ, O’Brien JT (2015) Baseline and longitudinal grey matter changes in newly diagnosed Parkinson’s disease: ICICLE-PD study. Brain 138:2974–2986. https://doi.org/10.1093/brain/awv211CrossRefPubMedPubMedCentral

Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H (2005) The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 53:695–699. https://doi.org/10.1111/j.1532-5415.2005.53221.xCrossRefPubMed

Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatr 55:181–184CrossRef

10.

Goetz CG, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stebbins GT, Stern MB, Tilley BC, Dodel R, Dubois B, Holloway R, Jankovic J, Kulisevsky J, Lang AE, Lees A, Leurgans S, LeWitt PA, Nyenhuis D, Olanow CW, Rascol O, Schrag A, Teresi JA, Van Hilten JJ, LaPelle N (2007) Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord 22:41–47. https://doi.org/10.1002/mds.21198CrossRefPubMed

11.

Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17:427–442CrossRefPubMed

12.

Schwab RS, England AC (1969) Projection techniques for evaluating surgery in Parkinson’s Disease. E. & S. Livingstone Ltd., Edinburgh

13.

Giladi N, Tal J, Azulay T, Rascol O, Brooks DJ, Melamed E, Oertel W, Poewe WH, Stocchi F, Tolosa E (2009) Validation of the freezing of gait questionnaire in patients with Parkinson’s disease. Mov Disord 24:655–661. https://doi.org/10.1002/mds.21745CrossRefPubMed

14.

Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56–62. https://doi.org/10.1136/jnnp.23.1.56CrossRefPubMedPubMedCentral

15.

Thompson E (2015) Hamilton Rating Scale for Anxiety (HAM-A). Occup Med (Lond) 65:601. https://doi.org/10.1093/occmed/kqv054CrossRefPubMed

16.

Sockeel P, Dujardin K, Devos D, Denève C, Destée A, Defebvre L (2006) The Lille apathy rating scale (LARS), a new instrument for detecting and quantifying apathy: validation in Parkinson’s disease. J Neurol Neurosurg Psychiatry 77:579–584. https://doi.org/10.1136/jnnp.2005.075929CrossRefPubMedPubMedCentral

17.

Rieu I, Martinez-Martin P, Pereira B, De Chazeron I, Verhagen Metman L, Jahanshahi M, Ardouin C, Chéreau I, Brefel-Courbon C, Ory-Magne F, Klinger H, Peyrol F, Schupbach M, Dujardin K, Tison F, Houeto JL, Krack P, Durif F (2015) International validation of a behavioral scale in Parkinson’s disease without dementia. Mov Disord 30:705–713. https://doi.org/10.1002/mds.26223CrossRefPubMed

18.

Shulman LM, Gruber-Baldini AL, Anderson KE, Fishman PS, Reich SG, Weiner WJ (2010) The clinically important difference on the unified Parkinson’s disease rating scale. Arch Neurol 67:64–70. https://doi.org/10.1001/archneurol.2009.295CrossRefPubMed

19.

Lhommée E, Wojtecki L, Czernecki V, Witt K, Maier F, Tonder L, Timmermann L, Hälbig TD, Pineau F, Durif F, Witjas T, Pinsker M, Mehdorn M, Sixel-Döring F, Kupsch A, Krüger R, Elben S, Chabardès S, Thobois S, Brefel-Courbon C, Ory-Magne F, Regis J-M, Maltête D, Sauvaget A, Rau J, Schnitzler A, Schüpbach M, Schade-Brittinger C, Deuschl G, Houeto J-L, Krack P, Negovanska V, Welter M-L, Corvol J-C, Agid Y, Navarro S, Meier N, Hartmann A, Hesekamp H, Cornu P, Möller B, Nebel A, Raethjen J, Knudsen K, Volkmann J, Falk D, Paschen S, Meister I, Kuhn J, Donner K, Kessler J, Barbe M, Fink G, Maarouf M, Kühn A, Müller B, Faust K, Gruber D, Schneider G-H, Seigneuret E, Pollak P, Fraix V, Kistner A, Rascol O, Arbus C, Danet L, Chaynes P, Groiss SJ, Hartmann C, Südmeyer M, Partowinia-Peters M, Vesper J, Ledily S, Damier P, Raoul S, Trenkwalder C, Richter-Dreske W, Wächter T, Weiss D, Eusebio A, Azulay JP, Polo G, Pinto S, Levin J, Dornier S, Pene F, Hourton D, Quintin M, Hoffart-Jourdain C, Brocvielle H, Balthasar K, Stein M, Harnisch S, Reuss A, Aminossadati B, Nasemann C, Oertel W, Bataille B, Hellwig D, Gharabaghi A, Amtage F, Mertens P, Kloss M, Post B, Speelman H (2018) Behavioural outcomes of subthalamic stimulation and medical therapy versus medical therapy alone for Parkinson’s disease with early motor complications (EARLYSTIM trial): secondary analysis of an open-label randomised trial. Lancet Neurol 17:223–231. https://doi.org/10.1016/S1474-4422(18)30035-8CrossRefPubMed

20.

Li A, Yue L, Xiao S, Liu M (2022) Cognitive Function Assessment and Prediction for Subjective Cognitive Decline and Mild Cognitive Impairment. Brain Imaging Behav 16:645–658. https://doi.org/10.1007/s11682-021-00545-1CrossRefPubMed

21.

Bender R, Lange S (2001) Adjusting for multiple testing–when and how? J Clin Epidemiol 54:343–349. https://doi.org/10.1016/s0895-4356(00)00314-0CrossRefPubMed

22.

Feise RJ (2002) Do multiple outcome measures require p-value adjustment? BMC Med Res Methodol 2:8CrossRefPubMedPubMedCentral

23.

Ibarretxe-Bilbao N, Junque C, Segura B, Baggio HC, Marti MJ, Valldeoriola F, Bargallo N, Tolosa E (2012) Progression of cortical thinning in early Parkinson’s disease: Cortical Thinning in Early PD. Mov Disord 27:1746–1753. https://doi.org/10.1002/mds.25240CrossRefPubMed

24.

Mollenhauer B, Zimmermann J, Sixel-Döring F, Focke NK, Wicke T, Ebentheuer J, Schaumburg M, Lang E, Trautmann E, Zetterberg H, Taylor P, Friede T, Trenkwalder C (2016) Monitoring of 30 marker candidates in early Parkinson disease as progression markers. Neurology 87:168–177. https://doi.org/10.1212/WNL.0000000000002651CrossRefPubMedPubMedCentral

25.

Jia X, Liang P, Li Y, Shi L, Wang D, Li K (2015) Longitudinal Study of Gray Matter Changes in Parkinson Disease. AJNR Am J Neuroradiol 36:2219–2226. https://doi.org/10.3174/ajnr.A4447CrossRefPubMedPubMedCentral

26.

Melzer TR, Myall DJ, MacAskill MR, Pitcher TL, Livingston L, Watts R, Keenan RJ, Dalrymple-Alford JC, Anderson TJ (2015) Tracking Parkinson’s Disease over One Year with Multimodal Magnetic Resonance Imaging in a Group of Older Patients with Moderate Disease. PLoS ONE. 10:e0143923. https://doi.org/10.1371/journal.pone.0143923CrossRefPubMedPubMedCentral

27.

Blair JC, Barrett MJ, Patrie J, Flanigan JL, Sperling SA, Elias WJ, Druzgal TJ (2019) Brain MRI Reveals Ascending Atrophy in Parkinson’s Disease Across Severity. Front Neurol 10:1329. https://doi.org/10.3389/fneur.2019.01329CrossRefPubMedPubMedCentral

28.

Oh BH, Moon HC, Kim A, Kim HJ, Cheong CJ, Park YS (2021) Prefrontal and hippocampal atrophy using 7-tesla magnetic resonance imaging in patients with Parkinson’s disease. Acta Radiol Open 10:2058460120988097. https://doi.org/10.1177/2058460120988097CrossRefPubMedPubMedCentral

29.

Ramírez-Ruiz B, Martí MJ, Tolosa E, Bartrés-Faz D, Summerfield Ch, Salgado-Pineda P, Gómez-Ansón B, Junqué C (2005) Longitudinal evaluation of cerebral morphological changes in Parkinson’s disease with and without dementia. J Neurol 252:1345–1352. https://doi.org/10.1007/s00415-005-0864-2CrossRefPubMed

30.

Benarroch EE (2015) The amygdala: Functional organization and involvement in neurologic disorders. Neurology 84:313–324. https://doi.org/10.1212/WNL.0000000000001171CrossRefPubMed

31.

Ibarretxe-Bilbao N, Ramírez-Ruiz B, Tolosa E, Martí MJ, Valldeoriola F, Bargalló N, Junqué C (2008) Hippocampal head atrophy predominance in Parkinson’s disease with hallucinations and with dementia. J Neurol 255:1324–1331. https://doi.org/10.1007/s00415-008-0885-8CrossRefPubMed

32.

Carey G, Görmezoğlu M, de Jong JJA, Hofman PAM, Backes WH, Dujardin K, Leentjens AFG (2021) Neuroimaging of Anxiety in Parkinson’s Disease: A Systematic Review. Mov Disord 36:327–339. https://doi.org/10.1002/mds.28404CrossRefPubMed

33.

Thobois S, Prange S, Sgambato-Faure V, Tremblay L, Broussolle E (2017) Imaging the Etiology of Apathy, Anxiety, and Depression in Parkinson’s Disease: Implication for Treatment. Curr Neurol Neurosci Rep 17:76. https://doi.org/10.1007/s11910-017-0788-0CrossRefPubMed

34.

Melzer TR, Watts R, MacAskill MR, Pitcher TL, Livingston L, Keenan RJ, Dalrymple-Alford JC, Anderson TJ (2012) Grey matter atrophy in cognitively impaired Parkinson’s disease. J Neurol Neurosurg Psychiatry 83:188–194. https://doi.org/10.1136/jnnp-2011-300828CrossRefPubMed

35.

Kamagata K, Motoi Y, Hori M, Suzuki M, Nakanishi A, Shimoji K, Kyougoku S, Kuwatsuru R, Sasai K, Abe O, Mizuno Y, Aoki S, Hattori N (2011) Posterior hypoperfusion in Parkinson’s disease with and without dementia measured with arterial spin labeling MRI. J Magn Reson Imaging 33:803–807. https://doi.org/10.1002/jmri.22515CrossRefPubMed

36.

Hosokai Y, Nishio Y, Hirayama K, Takeda A, Ishioka T, Sawada Y, Suzuki K, Itoyama Y, Takahashi S, Fukuda H, Mori E (2009) Distinct patterns of regional cerebral glucose metabolism in Parkinson’s disease with and without mild cognitive impairment. Mov Disord 24:854–862. https://doi.org/10.1002/mds.22444CrossRefPubMed

37.

Vogt BA (2019) Cingulate cortex in Parkinson’s disease. Handb Clin Neurol 166:253–266. https://doi.org/10.1016/B978-0-444-64196-0.00013-3CrossRefPubMed

38.

de Schipper LJ, van der Grond J, Marinus J, Henselmans JML, van Hilten JJ (2017) Loss of integrity and atrophy in cingulate structural covariance networks in Parkinson’s disease. NeuroImage 15:587–593. https://doi.org/10.1016/j.nicl.2017.05.012CrossRefPubMedPubMedCentral

39.

Goldman JG, Stebbins GT, Dinh V, Bernard B, Merkitch D, deToledo-Morrell L, Goetz CG (2014) Visuoperceptive region atrophy independent of cognitive status in patients with Parkinson’s disease with hallucinations. Brain. 137:849–859. https://doi.org/10.1093/brain/awt360CrossRefPubMedPubMedCentral

40.

Vercruysse S, Leunissen I, Vervoort G, Vandenberghe W, Swinnen S, Nieuwboer A (2015) Microstructural changes in white matter associated with freezing of gait in Parkinson’s disease: FOg-Related White Matter Changes. Mov Disord 30:567–576. https://doi.org/10.1002/mds.26130CrossRefPubMed

41.

Evers LJW, Krijthe JH, Meinders MJ, Bloem BR, Heskes TM (2019) Measuring Parkinson’s disease over time: the real-world within-subject reliability of the MDS-UPDRS. Mov Disord 34:1480–1487. https://doi.org/10.1002/mds.27790CrossRefPubMedPubMedCentral

42.

Aleksovski D, Miljkovic D, Bravi D, Antonini A (2018) Disease progression in Parkinson subtypes: the PPMI dataset. Neurol Sci 39:1971–1976. https://doi.org/10.1007/s10072-018-3522-zCrossRefPubMed

43.

Lessig S, Nie D, Xu R, Corey-Bloom J (2012) Changes on brief cognitive instruments over time in Parkinson’s disease. Mov Disord 27:1125–1128. https://doi.org/10.1002/mds.25070CrossRefPubMed

44.

Makarious MB, Leonard HL, Vitale D, Iwaki H, Sargent L, Dadu A, Violich I, Hutchins E, Saffo D, Bandres-Ciga S, Kim JJ, Song Y, Maleknia M, Bookman M, Nojopranoto W, Campbell RH, Hashemi SH, Botia JA, Carter JF, Craig DW, Van Keuren-Jensen K, Morris HR, Hardy JA, Blauwendraat C, Singleton AB, Faghri F, Nalls MA (2022) Multi-modality machine learning predicting Parkinson’s disease. NPJ Parkinsons Dis 8:35. https://doi.org/10.1038/s41531-022-00288-wCrossRefPubMedPubMedCentral

Titel: Volumetric changes and clinical trajectories in Parkinson’s disease: a prospective multicentric study
verfasst von: Ana Marques
Elise Macias
Bruno Pereira
Elodie Durand
Carine Chassain
Tiphaine Vidal
Luc Defebvre
Nicolas Carriere
Valerie Fraix
Elena Moro
Stéphane Thobois
Elise Metereau
Graziella Mangone
Marie Vidailhet
Jean-Christophe Corvol
Stéphane Lehéricy
Nicolas Menjot de Champfleur
Christian Geny
Umberto Spampinato
Wassilios G. Meissner
Solène Frismand
Emmanuelle Schmitt
Anne Doé de Maindreville
Christophe Portefaix
Philippe Remy
Gilles Fénelon
Jean Luc Houeto
Olivier Colin
Olivier Rascol
Patrice Peran
Jean-Marie Bonny
Maria Livia Fantini
Franck Durif
The R2* Study Group
Publikationsdatum: 31.08.2023
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Neurology / Ausgabe 12/2023
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-023-11947-0

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

29.05.2024 Hyponatriämie Nachrichten

Eine ältere Frau trinkt regelmäßig Sennesblättertee gegen ihre Verstopfung. Der scheint plötzlich gut zu wirken. Auf Durchfall und Erbrechen folgt allerdings eine Hyponatriämie. Nach deren Korrektur kommt es plötzlich zu progredienten Kognitions- und Verhaltensstörungen.

Schutz der Synapsen bei Alzheimer

29.05.2024 Morbus Alzheimer Nachrichten

Mit einem Neurotrophin-Rezeptor-Modulator lässt sich möglicherweise eine bestehende Alzheimerdemenz etwas abschwächen: Erste Phase-2-Daten deuten auf einen verbesserten Synapsenschutz.

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Background

Objective

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2023

Recurrent infarcts from thyroid cartilage compression of an aberrant vertebral artery: rare, easily overlooked, but treatable

Interaction of sex and onset site on the disease trajectory of amyotrophic lateral sclerosis

Frequency and predictors of poststroke epilepsy after mechanical thrombectomy for large vessel occlusion stroke: results from a multicenter cohort study

Sensory neuropathy in amyotrophic lateral sclerosis: a systematic review

Predicting neurologic recovery after severe acute brain injury using resting-state networks